BUCCALINE

This brand name is authorized in New Zealand.

Active ingredients

The drug BUCCALINE contains a combination of these active pharmaceutical ingredients (APIs):

1	Haemophilus influenzae type B 1500 million organisms (inactivated "germs") UNII F2TW0N64FI - HAEMOPHILUS INFLUENZAE TYPE B
	Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease.
	Read more about Haemophilus influenzae B
2	Pneumococcus I,II,III 1000 million organisms (inactivated "germs") UNII BT6U234YR2 - STREPTOCOCCUS PNEUMONIAE
	Read more about Pneumococcus, purified polysaccharides antigen
3	Staphylococcus aureus 1000 million organisms (inactivated "germs") UNII O478WX4004 - STAPHYLOCOCCUS AUREUS
4	Streptococcus agalactiae 1000 million organisms (inactivated "germs") UNII 2B3763S671 - STREPTOCOCCUS AGALACTIAE

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07AX	Other bacterial vaccines	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines
Discover more medicines within J07AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NZ	Medicines and Medical Devices Safety Authority	449